ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma; A retrospective case report
Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir.
Combination treatment with nivolumab and Rigvir of a progressive stage IIC skin melanoma patient.
A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®
Oncolytic viruses are a fast-developing cancer treatment field. Numerous viruses have been tested in clinical trials and three are approved. The first, Rigvir, is an immunomodulator with anti-tumour effect
Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery
Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro
Melanoma Unknown Primary Brain Metastasis Treatment with ECHO-7 Oncolytic Virus Rigvir: A Case Report
Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports
Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumor in a retrospective study
Jumeirah Lake Towers
Swiss Tower, office 204
P.O. Box 309073, Dubai, UAE
© 2020 International Virotherapy Center Limited. All Rights Reserved